

Jeffrey W Tyner

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3416865/publications.pdf>

Version: 2024-02-01

187
papers

11,539
citations

34016

52
h-index

31759

101
g-index

190
all docs

190
docs citations

190
times ranked

17088
citing authors

#	ARTICLE	IF	CITATIONS
1	A genome-wide CRISPR screen identifies regulators of MAPK and MTOR pathways that mediate resistance to sorafenib in acute myeloid leukemia. <i>Haematologica</i> , 2022, 107, 77-85.	1.7	20
2	MS4A3 promotes differentiation in chronic myeloid leukemia by enhancing common \hat{I}^2 -chain cytokine receptor endocytosis. <i>Blood</i> , 2022, 139, 761-778.	0.6	7
3	Associating drug sensitivity with differentiation status identifies effective combinations for acute myeloid leukemia. <i>Blood Advances</i> , 2022, 6, 3062-3067.	2.5	6
4	Dual BTK/SYK inhibition with CG-806 (luxetininib) disrupts B-cell receptor and Bcl-2 signaling networks in mantle cell lymphoma. <i>Cell Death and Disease</i> , 2022, 13, 246.	2.7	12
5	Functional proteomics of patient derived head and neck squamous cell carcinoma cells reveal novel applications of trametinib. <i>Cancer Biology and Therapy</i> , 2022, 23, 309-317.	1.5	3
6	Understanding Drug Sensitivity and Tackling Resistance in Cancer. <i>Cancer Research</i> , 2022, 82, 1448-1460.	0.4	24
7	Luxetininib (CG-806) Targets FLT3 and Clusters of Kinases Operative in Acute Myeloid Leukemia. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 1125-1135.	1.9	4
8	TNK1 is a ubiquitin-sensing kinase that can be targeted to block tumor growth. <i>FASEB Journal</i> , 2022, 36, .	0.2	0
9	Ex Vivo Analysis of Primary Tumor Specimens for Evaluation of Cancer Therapeutics. <i>Annual Review of Cancer Biology</i> , 2021, 5, 39-57.	2.3	9
10	Antileukemic efficacy of a potent artemisinin combined with sorafenib and venetoclax. <i>Blood Advances</i> , 2021, 5, 711-724.	2.5	10
11	Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory, or High-Risk Leukemias: A Report from the LEAP Consortium. <i>Cancer Discovery</i> , 2021, 11, 1424-1439.	7.7	16
12	An expanded universe of cancer targets. <i>Cell</i> , 2021, 184, 1142-1155.	13.5	135
13	The AML microenvironment catalyzes a stepwise evolution to gilteritinib resistance. <i>Cancer Cell</i> , 2021, 39, 999-1014.e8.	7.7	62
14	Bayesian multi-source regression and monocyte-associated gene expression predict BCL-2 inhibitor resistance in acute myeloid leukemia. <i>Npj Precision Oncology</i> , 2021, 5, 71.	2.3	12
15	Aurora A kinase as a target for therapy in \hat{I}^2 /TCF3-HLF rearranged acute lymphoblastic leukemia. <i>Haematologica</i> , 2021, 106, 2990-2994.	1.7	6
16	Monocytic Differentiation and AHR Signaling as Primary Nodes of BET Inhibitor Response in Acute Myeloid Leukemia. <i>Blood Cancer Discovery</i> , 2021, 2, 518-531.	2.6	23
17	Pharmacologic Targeting of Mcl-1 Induces Mitochondrial Dysfunction and Apoptosis in B-Cell Lymphoma Cells in a TP53- and BAX-Dependent Manner. <i>Clinical Cancer Research</i> , 2021, 27, 4910-4922.	3.2	22
18	A novel activating JAK1 mutation in chronic eosinophilic leukemia. <i>Blood Advances</i> , 2021, 5, 3581-3586.	2.5	9

#	ARTICLE	IF	CITATIONS
19	TNK1 is a ubiquitin-binding and 14-3-3-regulated kinase that can be targeted to block tumor growth. <i>Nature Communications</i> , 2021, 12, 5337.	5.8	14
20	Therapeutic Targeting of Mertk and BCL-2 in T-Cell and Early T-Precursor Acute Lymphoblastic Leukemia. <i>Blood</i> , 2021, 138, 1184-1184.	0.6	3
21	Insights on mechanisms of clonal evolution in chronic neutrophilic leukemia on ruxolitinib therapy. <i>Leukemia</i> , 2020, 34, 1684-1688.	3.3	8
22	Efficacy of Ruxolitinib in Patients With Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2020, 38, 1006-1018.	0.8	71
23	AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-xL, Induces Tumor Regression in Hematologic Cancer Models without Dose-limiting Thrombocytopenia. <i>Clinical Cancer Research</i> , 2020, 26, 6535-6549.	3.2	42
24	ERBB2/HER2 mutations are transforming and therapeutically targetable in leukemia. <i>Leukemia</i> , 2020, 34, 2798-2804.	3.3	16
25	Integrated analysis of patient samples identifies biomarkers for venetoclax efficacy and combination strategies in acute myeloid leukemia. <i>Nature Cancer</i> , 2020, 1, 826-839.	5.7	108
26	Discovery and characterization of targetable NTRK point mutations in hematologic neoplasms. <i>Blood</i> , 2020, 135, 2159-2170.	0.6	22
27	Reversible suppression of T cell function in the bone marrow microenvironment of acute myeloid leukemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 14331-14341.	3.3	55
28	Simultaneous kinase inhibition with ibrutinib and BCL2 inhibition with venetoclax offers a therapeutic strategy for acute myeloid leukemia. <i>Leukemia</i> , 2020, 34, 2342-2353.	3.3	18
29	Functional genomic analysis identifies drug targetable pathways in invasive and metastatic cutaneous squamous cell carcinoma. <i>Journal of Physical Education and Sports Management</i> , 2020, 6, a005439.	0.5	6
30	Genomic markers of midostaurin drug sensitivity in FLT3 mutated and FLT3 wild-type acute myeloid leukemia patients. <i>Oncotarget</i> , 2020, 11, 2807-2818.	0.8	5
31	Pharmacologic Targeting MCL1 with AZD5991 Induces Apoptosis and Mitochondrial Dysfunction in Non-Hodgkin Lymphoma (NHL) Cells. <i>Blood</i> , 2020, 136, 33-33.	0.6	0
32	A Functional Profiling of Microenvironmental Factors and Small Molecules Reveals Monocyte Chemoattractant Protein-1 Mediates Drug Resistance in Acute Myeloid Leukemia. <i>Blood</i> , 2020, 136, 11-12.	0.6	0
33	Evolution of Gilteritinib Resistance from Residual Disease to Relapse. <i>Blood</i> , 2020, 136, 4-5.	0.6	0
34	Genomic landscape of neutrophilic leukemias of ambiguous diagnosis. <i>Blood</i> , 2019, 134, 867-879.	0.6	55
35	SOX7 regulates MAPK/ERK-BIM mediated apoptosis in cancer cells. <i>Oncogene</i> , 2019, 38, 6196-6210.	2.6	32
36	What do functional genomics tell us about pathogenesis of AML?. <i>Best Practice and Research in Clinical Haematology</i> , 2019, 32, 101101.	0.7	1

#	ARTICLE	IF	CITATIONS
37	FGF2-FGFR1 signaling regulates release of Leukemia-Protective exosomes from bone marrow stromal cells. <i>ELife</i> , 2019, 8, .	2.8	38
38	Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants. <i>Cancer Cell</i> , 2019, 36, 431-443.e5.	7.7	137
39	The TP53 Apoptotic Network Is a Primary Mediator of Resistance to BCL2 Inhibition in AML Cells. <i>Cancer Discovery</i> , 2019, 9, 910-925.	7.7	215
40	Replication timing alterations in leukemia affect clinically relevant chromosome domains. <i>Blood Advances</i> , 2019, 3, 3201-3213.	2.5	15
41	CSF1R inhibitors exhibit antitumor activity in acute myeloid leukemia by blocking paracrine signals from support cells. <i>Blood</i> , 2019, 133, 588-599.	0.6	80
42	Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms. <i>Nature Communications</i> , 2019, 10, 244.	5.8	111
43	Predicting response to BET inhibitors using computational modeling: A BEAT AML project study. <i>Leukemia Research</i> , 2019, 77, 42-50.	0.4	16
44	Proteolysis targeting chimeric molecules as therapy for multiple myeloma: efficacy, biomarker and drug combinations. <i>Haematologica</i> , 2019, 104, 1209-1220.	1.7	30
45	LMTK3 is essential for oncogenic KIT expression in KIT-mutant GIST and melanoma. <i>Oncogene</i> , 2019, 38, 1200-1210.	2.6	16
46	DNA Methylation-Based Classification Highlights the Role of the JAK-STAT Pathway in Acute Myeloid Leukemia. <i>Blood</i> , 2019, 134, 1413-1413.	0.6	0
47	Illuminating biological pathways for drug targeting in head and neck squamous cell carcinoma. , 2019, 14, e0223639.		0
48	Illuminating biological pathways for drug targeting in head and neck squamous cell carcinoma. , 2019, 14, e0223639.		0
49	Illuminating biological pathways for drug targeting in head and neck squamous cell carcinoma. , 2019, 14, e0223639.		0
50	Illuminating biological pathways for drug targeting in head and neck squamous cell carcinoma. , 2019, 14, e0223639.		0
51	A novel <i>AGGF1-PDGFRb</i> fusion in pediatric T-cell acute lymphoblastic leukemia. <i>Haematologica</i> , 2018, 103, e87-e91.	1.7	8
52	Gain-of-function mutations in granulocyte colony-stimulating factor receptor (CSF3R) reveal distinct mechanisms of CSF3R activation. <i>Journal of Biological Chemistry</i> , 2018, 293, 7387-7396.	1.6	22
53	Two myeloid leukemia cases with rare FLT3 fusions. <i>Journal of Physical Education and Sports Management</i> , 2018, 4, a003079.	0.5	16
54	Targeting of colony-stimulating factor 1 receptor (CSF1R) in the CLL microenvironment yields antineoplastic activity in primary patient samples. <i>Oncotarget</i> , 2018, 9, 24576-24589.	0.8	36

#	ARTICLE	IF	CITATIONS
55	Functional genomic landscape of acute myeloid leukaemia. <i>Nature</i> , 2018, 562, 526-531.	13.7	907
56	Maintenance and pharmacologic targeting of ROR1 protein levels via UHRF1 in t(1;19) pre-B-ALL. <i>Oncogene</i> , 2018, 37, 5221-5232.	2.6	8
57	Induction of anaplastic lymphoma kinase (ALK) as a novel mechanism of EGFR inhibitor resistance in head and neck squamous cell carcinoma patient-derived models. <i>Cancer Biology and Therapy</i> , 2018, 19, 921-933.	1.5	12
58	Disparate effects of <i>Shb</i> gene deficiency on disease characteristics in murine models of myeloid, B-cell, and T-cell leukemia. <i>Tumor Biology</i> , 2018, 40, 101042831877147.	0.8	4
59	Dual inhibition of JAK1/2 kinases and BCL2: a promising therapeutic strategy for acute myeloid leukemia. <i>Leukemia</i> , 2018, 32, 2025-2028.	3.3	16
60	ARID1A and CEBP β cooperatively inhibit UCA1 transcription in breast cancer. <i>Oncogene</i> , 2018, 37, 5939-5951.	2.6	24
61	Synthetic lethality of TNK2 inhibition in PTPN11-mutant leukemia. <i>Science Signaling</i> , 2018, 11, .	1.6	16
62	Biomarkers Predicting Venetoclax Sensitivity and Strategies for Venetoclax Combination Treatment. <i>Blood</i> , 2018, 132, 175-175.	0.6	18
63	CG'806, a First-in-Class Pan-FLT3/Pan-BTK Inhibitor, Exhibits Broader and Greater Potency Than Ibrutinib Against Primary and Cultured Malignant B Cells. <i>Blood</i> , 2018, 132, 3503-3503.	0.6	0
64	Characterizing Population Heterogeneity and Signaling Changes in Chronic Myeloid Leukemia Stem and Progenitor Cells upon Combined Treatment with Imatinib and MEK Inhibitors Using Quantitative Single Cell Phospho-Imaging. <i>Blood</i> , 2018, 132, 4248-4248.	0.6	2
65	Combining p38MAPK Inhibitors with a Second Targeted Agent Enhances Blockade of Inflammatory Signaling-Mediated Survival in Acute Myeloid Leukemia Cells. <i>Blood</i> , 2018, 132, 2726-2726.	0.6	0
66	Significant In Vivo Sensitivity to Aurora Kinase Inhibition in TCF3-Hlf rearranged Acute Lymphoblastic Leukemia. <i>Blood</i> , 2018, 132, 4026-4026.	0.6	1
67	Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia. <i>Blood</i> , 2017, 129, e26-e37.	0.6	195
68	Integrating functional genomics to accelerate mechanistic personalized medicine. <i>Journal of Physical Education and Sports Management</i> , 2017, 3, a001370.	0.5	7
69	Pl γ enhances TLR β -dependent inflammatory responses in human mononuclear phagocytes. <i>American Journal of Reproductive Immunology</i> , 2017, 78, e12709.	1.2	13
70	Turning the tide in myelodysplastic/myeloproliferative neoplasms. <i>Nature Reviews Cancer</i> , 2017, 17, 425-440.	12.8	117
71	Identification of a Novel SYK/c-MYC/MALAT1 Signaling Pathway and Its Potential Therapeutic Value in Ewing Sarcoma. <i>Clinical Cancer Research</i> , 2017, 23, 4376-4387.	3.2	46
72	Identification of Interleukin-1 by Functional Screening as a Key Mediator of Cellular Expansion and Disease Progression in Acute Myeloid Leukemia. <i>Cell Reports</i> , 2017, 18, 3204-3218.	2.9	187

#	ARTICLE	IF	CITATIONS
73	BCL6 promotes glioma and serves as a therapeutic target. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 3981-3986.	3.3	58
74	Genomics of chronic neutrophilic leukemia. Blood, 2017, 129, 715-722.	0.6	74
75	CPX-351 exhibits potent and direct ex vivo cytotoxicity against AML blasts with enhanced efficacy for cells harboring the FLT3-ITD mutation. Leukemia Research, 2017, 53, 39-49.	0.4	22
76	Targeting super-enhancer-associated oncogenes in oesophageal squamous cell carcinoma. Gut, 2017, 66, 1358-1368.	6.1	169
77	Super-Enhancers Promote Transcriptional Dysregulation in Nasopharyngeal Carcinoma. Cancer Research, 2017, 77, 6614-6626.	0.4	103
78	Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoid-derived hematologic malignancies. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E7554-E7563.	3.3	86
79	Metabolic reprogramming ensures cancer cell survival despite oncogenic signaling blockade. Genes and Development, 2017, 31, 2067-2084.	2.7	57
80	Kinase Inhibitor Screening in Myeloid Malignancies. Hematology/Oncology Clinics of North America, 2017, 31, 693-704.	0.9	3
81	Unpaired Extracellular Cysteine Mutations of CSF3R Mediate Gain or Loss of Function. Cancer Research, 2017, 77, 4258-4267.	0.4	10
82	UNC2025, a MERTK Small-Molecule Inhibitor, Is Therapeutically Effective Alone and in Combination with Methotrexate in Leukemia Models. Clinical Cancer Research, 2017, 23, 1481-1492.	3.2	58
83	EPHB4 is a therapeutic target in AML and promotes leukemia cell survival via AKT. Blood Advances, 2017, 1, 1635-1644.	2.5	21
84	Kinase profiling of liposarcomas using RNAi and drug screening assays identified druggable targets. Journal of Hematology and Oncology, 2017, 10, 173.	6.9	25
85	Recent Progress in Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia. Current Hematologic Malignancy Reports, 2017, 12, 432-441.	1.2	16
86	Cholesterol esterification inhibition and imatinib treatment synergistically inhibit growth of BCR-ABL mutation-independent resistant chronic myelogenous leukemia. PLoS ONE, 2017, 12, e0179558.	1.1	41
87	Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors. Oncotarget, 2017, 8, 22606-22615.	0.8	13
88	Small molecule inhibitor screening identified HSP90 inhibitor 17-AAG as potential therapeutic agent for gallbladder cancer. Oncotarget, 2017, 8, 26169-26184.	0.8	21
89	JAKed up phenotype of CEBPA-mutant AML. Blood, 2016, 127, 2946-2947.	0.6	1
90	RNAi Screening of Leukemia Cells Using Electroporation. Methods in Molecular Biology, 2016, 1470, 85-94.	0.4	5

#	ARTICLE	IF	CITATIONS
91	FGF2 from Marrow Microenvironment Promotes Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia. <i>Cancer Research</i> , 2016, 76, 6471-6482.	0.4	110
92	Alterations in acute myeloid leukaemia bone marrow stromal cell exosome content coincide with gains in tyrosine kinase inhibitor resistance. <i>British Journal of Haematology</i> , 2016, 172, 983-986.	1.2	71
93	Targeting BCL-2 and ABL/LYN in Philadelphia chromosome-positive acute lymphoblastic leukemia. <i>Science Translational Medicine</i> , 2016, 8, 354ra114.	5.8	65
94	Ultrasensitive proteomic quantitation of cellular signaling by digitized nanoparticle-protein counting. <i>Scientific Reports</i> , 2016, 6, 28163.	1.6	7
95	Mutant calreticulin-expressing cells induce monocyte hyperreactivity through a paracrine mechanism. <i>American Journal of Hematology</i> , 2016, 91, 211-219.	2.0	29
96	Identification and Characterization of Tyrosine Kinase Nonreceptor 2 Mutations in Leukemia through Integration of Kinase Inhibitor Screening and Genomic Analysis. <i>Cancer Research</i> , 2016, 76, 127-138.	0.4	31
97	The Colony-Stimulating Factor 3 Receptor T640N Mutation Is Oncogenic, Sensitive to JAK Inhibition, and Mimics T618I. <i>Clinical Cancer Research</i> , 2016, 22, 757-764.	3.2	40
98	Cytokine-Mediated Inflammatory Pathways Promote Clonal Evolution and Disease Progression in Acute Myeloid Leukemia. <i>Blood</i> , 2016, 128, 1688-1688.	0.6	41
99	Effective Combination of CPX-351 with FLT3 Inhibitors in AML Blasts Harboring the FLT3-ITD Mutation. <i>Blood</i> , 2016, 128, 5124-5124.	0.6	9
100	Combined targeting of SET and tyrosine kinases provides an effective therapeutic approach in human T-cell acute lymphoblastic leukemia. <i>Oncotarget</i> , 2016, 7, 84214-84227.	0.8	26
101	What's different about atypical CML and chronic neutrophilic leukemia?. <i>Hematology American Society of Hematology Education Program</i> , 2015, 2015, 264-271.	0.9	38
102	Therapeutically Targetable ALK Mutations in Leukemia. <i>Cancer Research</i> , 2015, 75, 2146-2150.	0.4	20
103	Self-Enforcing Feedback Activation between BCL6 and Pre-B Cell Receptor Signaling Defines a Distinct Subtype of Acute Lymphoblastic Leukemia. <i>Cancer Cell</i> , 2015, 27, 409-425.	7.7	109
104	The ITIM-containing receptor LAIR1 is essential for acute myeloid leukaemia development. <i>Nature Cell Biology</i> , 2015, 17, 665-677.	4.6	112
105	YM155 potently kills acute lymphoblastic leukemia cells through activation of the DNA damage pathway. <i>Journal of Hematology and Oncology</i> , 2015, 8, 39.	6.9	32
106	Crosstalk between KIT and FGFR3 Promotes Gastrointestinal Stromal Tumor Cell Growth and Drug Resistance. <i>Cancer Research</i> , 2015, 75, 880-891.	0.4	81
107	Activation of protein phosphatase 2A tumor suppressor as potential treatment of pancreatic cancer. <i>Molecular Oncology</i> , 2015, 9, 889-905.	2.1	51
108	Mutations in G protein β subunits promote transformation and kinase inhibitor resistance. <i>Nature Medicine</i> , 2015, 21, 71-75.	15.2	106

#	ARTICLE	IF	CITATIONS
109	CSF1R Inhibition Targets AML Cells By Depleting Supportive Microenvironmental Signal from CD14+ Monocytes. <i>Blood</i> , 2015, 126, 3824-3824.	0.6	2
110	Small molecule inhibitor screen identifies synergistic activity of the bromodomain inhibitor CPI203 and bortezomib in drug resistant myeloma. <i>Oncotarget</i> , 2015, 6, 18921-18932.	0.8	45
111	Src and STAT3 inhibitors synergize to promote tumor inhibition in renal cell carcinoma. <i>Oncotarget</i> , 2015, 6, 44675-44687.	0.8	27
112	Genomic landscape of liposarcoma. <i>Oncotarget</i> , 2015, 6, 42429-42444.	0.8	94
113	Durable Disease Control with MEK Inhibition in a Patient with NRAS-mutated Atypical Chronic Myeloid Leukemia. <i>Cureus</i> , 2015, 7, e414.	0.2	29
114	Placental Growth Factor Enhances Toll-like Receptor-Induced Inflammatory Cytokine Gene Expression Transcriptionally in Human Mononuclear Phagocytes. <i>Blood</i> , 2015, 126, 1006-1006.	0.6	0
115	PDGFR β reverses EphB4 signaling in alveolar rhabdomyosarcoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 6383-6388.	3.3	33
116	Ligand Independence of the T618I Mutation in the Colony-stimulating Factor 3 Receptor (CSF3R) Protein Results from Loss of O-Linked Glycosylation and Increased Receptor Dimerization. <i>Journal of Biological Chemistry</i> , 2014, 289, 5820-5827.	1.6	51
117	Functional Genomics for Personalized Cancer Therapy. <i>Science Translational Medicine</i> , 2014, 6, 243fs26.	5.8	13
118	TSLP signaling pathway map: a platform for analysis of TSLP-mediated signaling. <i>Database: the Journal of Biological Databases and Curation</i> , 2014, 2014, bau007-bau007.	1.4	71
119	Heterogeneity of Pancreatic Cancer Metastases in a Single Patient Revealed by Quantitative Proteomics. <i>Molecular and Cellular Proteomics</i> , 2014, 13, 2803-2811.	2.5	52
120	Significant clinical response to JAK1/2 inhibition in a patient with CSF3R-T618I-positive atypical chronic myeloid leukemia. <i>Leukemia Research Reports</i> , 2014, 3, 67-69.	0.2	62
121	Functional integration of acute myeloid leukemia into the vascular niche. <i>Leukemia</i> , 2014, 28, 1978-1987.	3.3	75
122	Antagonism of SET Using OP449 Enhances the Efficacy of Tyrosine Kinase Inhibitors and Overcomes Drug Resistance in Myeloid Leukemia. <i>Clinical Cancer Research</i> , 2014, 20, 2092-2103.	3.2	108
123	Ponatinib overcomes FGF2-mediated resistance in CML patients without kinase domain mutations. <i>Blood</i> , 2014, 123, 1516-1524.	0.6	44
124	Corepressor Rcor1 is essential for murine erythropoiesis. <i>Blood</i> , 2014, 123, 3175-3184.	0.6	24
125	Belinostat and panobinostat (HDACi): in vitro and in vivo studies in thyroid cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2013, 139, 1507-1514.	1.2	37
126	Comparison of methods to identify aberrant expression patterns in individual patients: augmenting our toolkit for precision medicine. <i>Genome Medicine</i> , 2013, 5, 103.	3.6	7

#	ARTICLE	IF	CITATIONS
127	The Selective Syk Inhibitor P505-15 (PRT062607) Inhibits B Cell Signaling and Function In Vitro and In Vivo and Augments the Activity of Fludarabine in Chronic Lymphocytic Leukemia. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2013, 344, 378-387.	1.3	40
128	The new genetics of chronic neutrophilic leukemia and atypical CML: implications for diagnosis and treatment. <i>Blood</i> , 2013, 122, 1707-1711.	0.6	162
129	Imatinib and Dasatinib Inhibit Hemangiosarcoma and Implicate PDGFR- $\hat{2}$ and Src in Tumor Growth. <i>Translational Oncology</i> , 2013, 6, 158-177.	1.7	24
130	Threshold Levels of ABL Tyrosine Kinase Inhibitors Retained in Chronic Myeloid Leukemia Cells Determine Their Commitment to Apoptosis. <i>Cancer Research</i> , 2013, 73, 3356-3370.	0.4	26
131	Oncogenic CSF3R Mutations in Chronic Neutrophilic Leukemia and Atypical CML. <i>New England Journal of Medicine</i> , 2013, 368, 1781-1790.	13.9	499
132	TYK2-STAT1-BCL2 Pathway Dependence in T-cell Acute Lymphoblastic Leukemia. <i>Cancer Discovery</i> , 2013, 3, 564-577.	7.7	122
133	Next-Generation Medicine: Combining BCR-ABL and Hedgehog-Targeted Therapies. <i>Clinical Cancer Research</i> , 2013, 19, 1309-1311.	3.2	4
134	HitWalker: variant prioritization for personalized functional cancer genomics. <i>Bioinformatics</i> , 2013, 29, 509-510.	1.8	9
135	Dynamic and Nuclear Expression of PDGFR $\hat{1}$ and IGF-1R in Alveolar Rhabdomyosarcoma. <i>Molecular Cancer Research</i> , 2013, 11, 1303-1313.	1.5	29
136	Kinase Pathway Dependence in Primary Human Leukemias Determined by Rapid Inhibitor Screening. <i>Cancer Research</i> , 2013, 73, 285-296.	0.4	134
137	The PI3K/Akt1 pathway enhances steady-state levels of FANCL. <i>Molecular Biology of the Cell</i> , 2013, 24, 2582-2592.	0.9	7
138	A molecular case report. <i>Cancer Biology and Therapy</i> , 2013, 14, 95-99.	1.5	3
139	Foretinib is a potent inhibitor of oncogenic ROS1 fusion proteins. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 19519-19524.	3.3	106
140	Causal role for JAK2 V617F in thrombosis. <i>Blood</i> , 2013, 122, 3705-3706.	0.6	18
141	The CSF3R T618I mutation causes a lethal neutrophilic neoplasia in mice that is responsive to therapeutic JAK inhibition. <i>Blood</i> , 2013, 122, 3628-3631.	0.6	95
142	A case study of personalized therapy for osteosarcoma. <i>Pediatric Blood and Cancer</i> , 2013, 60, 1313-1319.	0.8	21
143	OP449, a Novel SET Antagonist, Is Cytotoxic To Leukemia Cells and Enhances Efficacy Of Tyrosine Kinase Inhibitors In Drug-Resistant Myeloid Leukemias. <i>Blood</i> , 2013, 122, 2511-2511.	0.6	1
144	Immunoprecipitation of ROR1. <i>Bio-protocol</i> , 2013, 3, .	0.2	1

#	ARTICLE	IF	CITATIONS
145	ROR1 Flow Cytometry. <i>Bio-protocol</i> , 2013, 3, .	0.2	0
146	CSF3R T618I Mouse Bone Marrow Transplant Model Of Neutrophilic Leukemia. <i>Blood</i> , 2013, 122, 223-223.	0.6	1
147	Integrated Analysis Of CRLF2 Signaling In Acute Lymphoblastic Leukemia Identifies Polo-Like Kinase 1 As a Therapeutic Target. <i>Blood</i> , 2013, 122, 2667-2667.	0.6	0
148	Critical Role Of Interleukin Receptor Signaling In Acute Myeloid Leukemia Identified Using An RNAi Functional Screen. <i>Blood</i> , 2013, 122, 473-473.	0.6	0
149	The CSF3R T618I Mutation Found In Chronic Neutrophilic Leukemia Removes An O-Linked Glycosylation Site and Increases Receptor Dimerization. <i>Blood</i> , 2013, 122, 270-270.	0.6	0
150	FGF2 Promotes Resistance To Quizartinib In Vitro, and FGF2 Increases In The Marrow Of Patients Prior To Resistance. <i>Blood</i> , 2013, 122, 2541-2541.	0.6	0
151	The Beta-Subunit Of Heterotrimeric G Proteins Harbors Gain-Of-Function Mutations In Multiple Hematologic Malignancies. <i>Blood</i> , 2013, 122, 2510-2510.	0.6	0
152	FGF2 Mediates Resistance In CML Patients In The Absence Of Kinase Domain Mutations, and Resistance Is Overcome By Ponatinib. <i>Blood</i> , 2013, 122, 3983-3983.	0.6	0
153	JAK2 V617F down-modulates MPL. <i>Blood</i> , 2012, 119, 4579-4580.	0.6	1
154	p38 MAPK inhibition suppresses the TLR-hypersensitive phenotype in FANCC- and FANCA-deficient mononuclear phagocytes. <i>Blood</i> , 2012, 119, 1992-2002.	0.6	35
155	TSLP Signaling Network Revealed by SILAC-Based Phosphoproteomics. <i>Molecular and Cellular Proteomics</i> , 2012, 11, M112.017764.	2.5	47
156	Crosstalk between ROR1 and the Pre-B Cell Receptor Promotes Survival of t(1;19) Acute Lymphoblastic Leukemia. <i>Cancer Cell</i> , 2012, 22, 656-667.	7.7	153
157	An adaptive Src-“PDGFRA”-Raf axis in rhabdomyosarcoma. <i>Biochemical and Biophysical Research Communications</i> , 2012, 426, 363-368.	1.0	14
158	In vitro sensitivity to dasatinib in lymphoblasts from a patient with t(17;19)(q22;p13) gene rearrangement pre-acute lymphoblastic leukemia. <i>Pediatric Blood and Cancer</i> , 2012, 59, 576-579.	0.8	23
159	Potent Activity of Ponatinib (AP24534) in Models of FLT3-Driven Acute Myeloid Leukemia and Other Hematologic Malignancies. <i>Molecular Cancer Therapeutics</i> , 2011, 10, 1028-1035.	1.9	135
160	CAL-101, a p110 β selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. <i>Blood</i> , 2011, 117, 591-594.	0.6	682
161	The ABL Switch Control Inhibitor DCC-2036 Is Active against the Chronic Myeloid Leukemia Mutant BCR-ABL T315I and Exhibits a Narrow Resistance Profile. <i>Cancer Research</i> , 2011, 71, 3189-3195.	0.4	91
162	Rapid identification of therapeutic targets in hematologic malignancies via functional genomics. <i>Therapeutic Advances in Hematology</i> , 2011, 2, 83-93.	1.1	1

#	ARTICLE	IF	CITATIONS
163	Phosphoproteomics microarray screen reveals novel interaction between MPL and Tensin2. <i>Cell Cycle</i> , 2011, 10, 2621-2621.	1.3	0
164	CX-4945, An Orally Bioavailable Selective Inhibitor of Casein Kinase 2 (CK2), Exhibits Anti-Tumor Activity in Hematologic Malignancies.. <i>Blood</i> , 2011, 118, 3512-3512.	0.6	12
165	Flt3 Kinase Regulates Microvesicle Transfer of miRNA Between AML and Stromal Cells. <i>Blood</i> , 2011, 118, 1492-1492.	0.6	0
166	CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms. <i>Blood</i> , 2010, 115, 5232-5240.	0.6	216
167	MET Receptor Sequence Variants R970C and T992I Lack Transforming Capacity. <i>Cancer Research</i> , 2010, 70, 6233-6237.	0.4	65
168	RNAi screen for rapid therapeutic target identification in leukemia patients. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 8695-8700.	3.3	110
169	AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance. <i>Cancer Cell</i> , 2009, 16, 401-412.	7.7	1,050
170	High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients. <i>Blood</i> , 2009, 113, 1749-1755.	0.6	119
171	Persistent activation of an innate immune response translates respiratory viral infection into chronic lung disease. <i>Nature Medicine</i> , 2008, 14, 633-640.	15.2	477
172	SGX393 inhibits the CML mutant Bcr-Abl ^{T315I} and preempts <i>in vitro</i> resistance when combined with nilotinib or dasatinib. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 5507-5512.	3.3	84
173	RNAi screening of the tyrosine kinome identifies therapeutic targets in acute myeloid leukemia. <i>Blood</i> , 2008, 111, 2238-2245.	0.6	67
174	High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemia. <i>Blood</i> , 2008, 111, 4788-4796.	0.6	84
175	Growth Arrest of BCR-ABL Positive Cells with a Sequence-Specific Polyamide-Chlorambucil Conjugate. <i>PLoS ONE</i> , 2008, 3, e3593.	1.1	9
176	A novel fusion of RBM6 to CSF1R in acute megakaryoblastic leukemia. <i>Blood</i> , 2007, 110, 323-333.	0.6	44
177	RNAi Functional Screening of the Tyrosine Kinome Identifies Therapeutic Targets in Acute Myeloid Leukemia Patients.. <i>Blood</i> , 2007, 110, 208-208.	0.6	0
178	Activating alleles of JAK3 in acute megakaryoblastic leukemia. <i>Cancer Cell</i> , 2006, 10, 65-75.	7.7	295
179	Blocking airway mucous cell metaplasia by inhibiting EGFR antiapoptosis and IL-13 transdifferentiation signals. <i>Journal of Clinical Investigation</i> , 2006, 116, 309-321.	3.9	231
180	Inhibition of T315I Bcr-Abl and Other Imatinib-Resistant Bcr-Abl Mutants by the Selective Abl Kinase Inhibitor SGX70393.. <i>Blood</i> , 2006, 108, 1373-1373.	0.6	3

#	ARTICLE	IF	CITATIONS
181	Identification of Tyrosine Kinase Mutations by Large-Scale DNA Sequencing in Patients with Chronic Myelomonocytic Leukemia/Atypical Chronic Myeloid Leukemia.. Blood, 2006, 108, 3606-3606.	0.6	0
182	Defining and Adjusting Divergent Host Responses to Viral Infection. Immunologic Research, 2005, 32, 123-142.	1.3	2
183	Acute and Chronic Airway Responses to Viral Infection: Implications for Asthma and Chronic Obstructive Pulmonary Disease. Proceedings of the American Thoracic Society, 2005, 2, 132-140.	3.5	50
184	CCL5-CCR5 interaction provides antiapoptotic signals for macrophage survival during viral infection. Nature Medicine, 2005, 11, 1180-1187.	15.2	263
185	“Hit-and-Run” Effects of Paramyxoviruses as a Basis for Chronic Respiratory Disease. Pediatric Infectious Disease Journal, 2004, 23, S235-S245.	1.1	12
186	Apoptosis in the Airways. American Journal of Respiratory Cell and Molecular Biology, 2003, 29, 3-7.	1.4	61
187	Immunity, Inflammation, and Remodeling in the Airway Epithelial Barrier: Epithelial-Viral-Allergic Paradigm. Physiological Reviews, 2002, 82, 19-46.	13.1	115